Skip to main content

Generic semaglutide update: 3 of 9 generic semaglutide products approved by Health Canada. See timeline →

Is Ozempic or Mounjaro covered in Saskatchewan?

By GLP1Prices Editorial · Plan rules checked November 14, 2026 · Sources under each section

Is Ozempic, Wegovy, Mounjaro or Zepbound covered by the Saskatchewan Drug Plan?

The Saskatchewan Drug Plan is for residents with valid Saskatchewan health coverage. It pays for the drugs on the Saskatchewan Formulary and, once approved, Exception Drug Status (EDS) drugs. What you pay depends on your program: a deductible and co-payment under Special Support, or the maximum per prescription of the Seniors' or Children's Drug Plan. Its answer for each drug:

Sources: saskatchewan.ca: The Saskatchewan Drug Plan (read November 14, 2026); Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026); saskatchewan.ca: Exception Drug Status (read November 14, 2026); saskatchewan.ca: Extended Benefits and Drug Plan (read November 14, 2026)

The short answer

The Saskatchewan Drug Plan pays for Ozempic and generic semaglutide only through Exception Drug Status (EDS), under the criteria in Appendix A of the Saskatchewan Formulary; some approvals are generated automatically, the others follow a request from your prescriber or pharmacist. Mounjaro and Zepbound are not on the Formulary, and Wegovy was not recommended for listing. Without coverage you pay the pharmacy's price: the lowest prices we list in Saskatchewan are below.

Sources: Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026); Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026); Saskatchewan Formulary Bulletin #226, February 1, 2023 (read November 14, 2026)

What you pay without coverage in Saskatchewan

When a drug is not a benefit, "Payment for the medication is the responsibility of the patient", and an EDS drug is paid only once EDS is approved. Without coverage, the pharmacy's price applies. These are the lowest prices we list in Saskatchewan, with the pharmacy and the date the price was last updated.

Sources: Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026); saskatchewan.ca: Exception Drug Status (read November 14, 2026)

DrugPublic plan statusLowest price we list in Saskatchewan
OzempicException Drug Status (EDS), possible online approval$255.41 at Walmart Pharmacy1mg/0.5mL pen, 1 pen · Updated November 20262 pharmacies listed
Generic semaglutide (Apo-Semaglutide)Exception Drug Status (EDS), possible online approval$103.16 at Sherwood Co-op Pharmacy2mg/3mL pen, 1 pen · Updated November 20261 pharmacy listed
MounjaroNot on the Saskatchewan FormularyNo price listed yet
WegovyNot recommended for Formulary listingNo price listed yet
ZepboundNot on the Saskatchewan Formulary$358 at Shoppers Drug Mart7.5mg/0.6mL pen, 1 pen · Updated November 20261 pharmacy listed

Status from the plan's own lists (sources under each section below). Prices are the lowest active price we list per drug in Saskatchewan, before any plan or savings card; a pharmacy may add a dispensing fee.

How the Saskatchewan Drug Plan decides what it pays

Saskatchewan residents "with valid Saskatchewan health coverage may be eligible for drug plan benefits", and what a prescription costs depends on the type of benefits you get. People whose health services are covered by a federal program are not eligible. "The Saskatchewan Formulary lists the drugs, which are covered by the Drug Plan."

Sources: saskatchewan.ca: The Saskatchewan Drug Plan (read November 14, 2026); Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026)

The Special Support Program is income-tested: it sets a deductible from your total family income and a co-payment from your family income and family drug costs, for each calendar year. The Seniors' Drug Plan (65 and older) and the Children's Drug Plan (children 14 and under) set a maximum you pay per prescription instead. You pay for drugs on the Formulary, or approved under EDS, according to your program.

Sources: saskatchewan.ca: Drug Cost Assistance (Special Support Program) (read November 14, 2026); saskatchewan.ca: Extended Benefits and Drug Plan (read November 14, 2026); saskatchewan.ca: Exception Drug Status (read November 14, 2026)

Exception Drug Status (EDS) makes a drug a Drug Plan benefit for one person: "An individual must meet certain medical criteria for an EDS drug to be approved as a Drug Plan benefit." A physician, nurse practitioner or pharmacist sends the request by telephone, mail, fax or email; you cannot send it yourself. The Drug Plan mails a letter with the drug, the effective date and the expiry date, and your health provider sends the renewal.

Sources: saskatchewan.ca: Exception Drug Status (read November 14, 2026); Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026)

Some EDS drugs can be approved through online EDS adjudication (OEA): the Drug Plan's system looks in your records for certain alternative medications, specific prescribers or age groups, and can then "generate an automatic EDS approval". If your record is incomplete, a regular EDS request is needed.

Source: Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026)

Appendix A also says "not all medications currently available on the market in Canada are benefits under the Saskatchewan Drug Plan or under the Exception Drug Status Program". When a requested drug is not a benefit, the patient and prescriber are told, and "Payment for the medication is the responsibility of the patient".

Source: Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026)

Ozempic and generic semaglutide in Saskatchewan

Status: Exception Drug Status (EDS), possible online approval

The Online Formulary Database (effective November 1, 2026) marks Ozempic, Apo-Semaglutide and Dr. Reddy's semaglutide as EDS drugs, and its DIN search finds the three Ozempic pens (DINs 02471469, 02471477 and 02540258) and the four generic pens (DINs 02568020, 02568012, 02567806 and 02567814).

Source: Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026)

Appendix A publishes the EDS criteria for the semaglutide 0.68 mg/mL and 1.34 mg/mL pens, "Ozempic and listed generics", and marks them for possible online EDS adjudication. The Drug Plan pays once EDS is approved, according to your deductible or co-payment, for the period in the approval letter.

Sources: Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026); saskatchewan.ca: Exception Drug Status (read November 14, 2026)

Ozempic prices in Saskatchewan · Generic semaglutide (Apo-Semaglutide) prices in Saskatchewan

Mounjaro in Saskatchewan

Status: Not on the Saskatchewan Formulary

The Online Formulary Database's name search finds no Mounjaro or tirzepatide, its DIN search does not find the Mounjaro KwikPen (DIN 02551950), and Appendix A has no tirzepatide entry. A drug that is not a benefit is paid by the patient.

Sources: Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026); Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026)

Wegovy in Saskatchewan

Status: Not recommended for Formulary listing

Saskatchewan Formulary Bulletin #226 (February 1, 2023) lists the semaglutide 2.4 mg pens (Wegovy) among "The following products were NOT RECOMMENDED for Formulary Listing". Bulletins #230 (June 2023) to #272 (November 1, 2026) name no semaglutide product, and the Online Formulary Database does not find Wegovy (DIN 02528525).

Sources: Saskatchewan Formulary Bulletin #226, February 1, 2023 (read November 14, 2026); Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026)

Zepbound in Saskatchewan

Status: Not on the Saskatchewan Formulary

Zepbound is tirzepatide too. The Online Formulary Database finds no Zepbound (DIN 02557509) or tirzepatide, and Appendix A has no tirzepatide entry.

Sources: Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026); Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026)

Zepbound prices in Saskatchewan

Private and workplace plans

An employer or other private plan sets its own rules. Saskatchewan's EDS approval letter can be kept for co-ordinating benefits with a private health plan. Sun Life and Canada Life put Ozempic on prior authorization: your prescriber fills in part of the insurer's form, and the insurer pays only once it approves the request. Wegovy is covered only on plans that include it. Ask your insurer about Mounjaro and Zepbound, or check with the Coverage Checker.

Sources: saskatchewan.ca: Exception Drug Status (read November 14, 2026); Sun Life: Prior Authorization Form, OZEMPIC (semaglutide) or generic products, 4233-PA-OZE-E-09-26 (read November 14, 2026); Sun Life: report for plan sponsors on drug management strategies (November 2025) (read November 14, 2026); Canada Life: Workplace benefits, prior-authorization forms (read November 14, 2026); Canada Life: Drug Prior Authorization Form, semaglutide (Ozempic and generics), M6453(Ozempic)-10/26 (read November 14, 2026); Canada Life: Drug Prior Authorization Form, Wegovy (semaglutide), M6453(Wegovy)-8/26 (read November 14, 2026)

Getting a prescription online in Saskatchewan

Each of these drugs needs a prescription: Health Canada's Drug Product Database puts Ozempic, Wegovy, Mounjaro, Zepbound and Apo-Semaglutide in its Prescription schedule. If you don't have a prescriber, our guides list the online providers we track, the provinces each one serves and what they charge.

Sources: Health Canada Drug Product Database: Ozempic, DIN 02471469 (semaglutide; Schedule: Prescription, Schedule D) (read November 11, 2026); Health Canada Drug Product Database: Wegovy, DIN 02528525 (semaglutide; Schedule: Prescription, Schedule D) (read November 11, 2026); Health Canada Drug Product Database: Mounjaro KwikPen, DIN 02551950 (tirzepatide; Schedule: Prescription) (read November 11, 2026); Health Canada Drug Product Database: Zepbound, DIN 02557509 (tirzepatide; Schedule: Prescription) (read November 11, 2026); Health Canada Drug Product Database: Apo-Semaglutide Injection, DIN 02568012 (semaglutide; Schedule: Prescription) (read November 11, 2026)

Where are you in your GLP-1 journey?

Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.

Frequently asked questions

Does the Saskatchewan Drug Plan cover Ozempic?

Through Exception Drug Status. When we read the Saskatchewan Formulary on November 14, 2026 (database effective November 1, 2026), Ozempic and the Apotex and Dr. Reddy's generic pens were EDS drugs, and Appendix A published their criteria. The Drug Plan pays once EDS is approved, automatically through online adjudication or on your prescriber's or pharmacist's request, according to your deductible or co-payment.

Sources: Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026); Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026); saskatchewan.ca: Exception Drug Status (read November 14, 2026)

Is Mounjaro covered in Saskatchewan?

Not by the Saskatchewan Drug Plan. The Online Formulary Database finds no Mounjaro or tirzepatide, and Appendix A has no tirzepatide entry. You pay the pharmacy price unless a private plan covers it.

Sources: Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026); Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026)

How much is Ozempic in Saskatchewan without insurance?

The lowest Ozempic price we list in Saskatchewan is $255.41 at Walmart Pharmacy (1mg/0.5mL pen, 1 pen, updated November 2026). The lowest generic semaglutide (Apo-Semaglutide) price we list in Saskatchewan is $103.16 at Sherwood Co-op Pharmacy (2mg/3mL pen, 1 pen, updated November 2026). A pharmacy may add a dispensing fee. Every pharmacy's price is on Ozempic prices in Saskatchewan.

How much is Mounjaro in Saskatchewan without coverage?

The lowest Zepbound price we list in Saskatchewan is $358 at Shoppers Drug Mart (7.5mg/0.6mL pen, 1 pen, updated November 2026). A pharmacy may add a dispensing fee. Every pharmacy's price is on Zepbound prices in Saskatchewan.

Is Wegovy covered in Saskatchewan?

No. Bulletin #226 (February 1, 2023) lists Wegovy among the products not recommended for Formulary listing, and the Online Formulary Database does not find it. A private plan may cover Wegovy if your plan includes it.

Sources: Saskatchewan Formulary Bulletin #226, February 1, 2023 (read November 14, 2026); Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026); Sun Life: optional drug category, prior authorization from October 15, 2024 (August 13, 2024) (read October 2, 2026); Canada Life: Wegovy prior authorization form M6453 ("not covered under all benefit plans") (read October 2, 2026)

Is Zepbound covered by the Saskatchewan Drug Plan?

No. The Online Formulary Database finds no Zepbound or tirzepatide product, and Appendix A has no tirzepatide entry.

Sources: Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026); Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026)

Who applies for Exception Drug Status in Saskatchewan?

A physician, nurse practitioner or pharmacist, by telephone, mail, fax or email; families and individuals cannot apply themselves. For drugs marked for online EDS adjudication, as semaglutide is, the Drug Plan's system can approve EDS automatically when it finds what it looks for in your records. The approval letter gives the effective date and the expiry date.

Sources: saskatchewan.ca: Exception Drug Status (read November 14, 2026); Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026)

Sources

  1. saskatchewan.ca: The Saskatchewan Drug Plan (read November 14, 2026): Residents "with valid Saskatchewan health coverage may be eligible for drug plan benefits"; costs of prescriptions vary with the type of benefits; people whose health services are covered under federal programs are not eligible.
  2. Saskatchewan Online Formulary Database (effective November 1, 2026): name and DIN searches (read November 14, 2026): "The Saskatchewan Formulary lists the drugs, which are covered by the Drug Plan." The name search offers Ozempic (EDS), Apo-Semaglutide Inj (EDS) and Semaglutide Inj (EDS) and finds no Mounjaro, Zepbound, tirzepatide, Wegovy, Rybelsus, Saxenda or liraglutide. The DIN search finds the Ozempic and generic semaglutide DINs (02471469, 02471477, 02540258, 02568020, 02568012, 02567806 and 02567814) and not Wegovy (02528525), Mounjaro (02551950) or Zepbound (02557509).
  3. saskatchewan.ca: Exception Drug Status (read November 14, 2026): "An individual must meet certain medical criteria for an EDS drug to be approved as a Drug Plan benefit." Physicians, nurse practitioners or pharmacists submit the request; families or individuals cannot. The approval letter gives the drug, the effective date and the expiry date, and can be kept for co-ordinating benefits with a private health plan; the health provider submits the renewal. You pay according to your deductible and/or co-payment.
  4. saskatchewan.ca: Extended Benefits and Drug Plan (read November 14, 2026): The programs, among them the Children's Drug Plan (children 14 and under) and the Seniors' Drug Plan (65 and older), each with a maximum amount per prescription, and the income-tested Special Support Program.
  5. Saskatchewan Formulary, Appendix A: Exception Drug Status Program (read November 14, 2026): Page 1: licensed healthcare providers apply by telephone, mail or fax; patients are notified by letter of the approval and its period; "not all medications currently available on the market in Canada are benefits under the Saskatchewan Drug Plan or under the Exception Drug Status Program", and when a drug is not a benefit "Payment for the medication is the responsibility of the patient"; online EDS adjudication (OEA): the Drug Plan's system "will look for certain alternative medications, specific prescibers or age groups in order to generate an automatic EDS approval", and if a patient's profile is incomplete "a traditional EDS request will be required". Page 100: semaglutide 0.68 mg/mL and 1.34 mg/mL pens, "Ozempic and listed generics", possible OEA, with the published criteria.
  6. Saskatchewan Formulary Bulletin #226, February 1, 2023 (read November 14, 2026): Page 2: the semaglutide 2.4 mg pre-filled pens (Wegovy) are among "The following products were NOT RECOMMENDED for Formulary Listing". Bulletins #230 (June 2023) to #272 (November 1, 2026) name no semaglutide or tirzepatide product.
  7. saskatchewan.ca: Drug Cost Assistance (Special Support Program) (read November 14, 2026): A voluntary income-tested program: a deductible based on total family income and a copayment based on family income and family drug costs, for each calendar year. You pay for drugs on the Formulary or approved under Exception Drug Status according to that deductible and copayment.
  8. Sun Life: Prior Authorization Form, OZEMPIC (semaglutide) or generic products, 4233-PA-OZE-E-09-26 (read November 14, 2026)
  9. Sun Life: report for plan sponsors on drug management strategies (November 2025) (read November 14, 2026): Page 6 lists the five drugs of the category, Saxenda, Wegovy and Zepbound among them; page 9 has the optional category, its two strategies and Ozempic’s prior authorization.
  10. Canada Life: Workplace benefits, prior-authorization forms (read November 14, 2026): The list of forms: Ozempic and generics, Plosbrio, Poviztra, Rybelsus, Wegovy, Mounjaro and Zepbound; no Saxenda form.
  11. Canada Life: Drug Prior Authorization Form, semaglutide (Ozempic and generics), M6453(Ozempic)-10/26 (read November 14, 2026)
  12. Canada Life: Drug Prior Authorization Form, Wegovy (semaglutide), M6453(Wegovy)-8/26 (read November 14, 2026)
  13. Health Canada Drug Product Database: Ozempic, DIN 02471469 (semaglutide; Schedule: Prescription, Schedule D) (read November 11, 2026)
  14. Health Canada Drug Product Database: Wegovy, DIN 02528525 (semaglutide; Schedule: Prescription, Schedule D) (read November 11, 2026)
  15. Health Canada Drug Product Database: Mounjaro KwikPen, DIN 02551950 (tirzepatide; Schedule: Prescription) (read November 11, 2026)
  16. Health Canada Drug Product Database: Zepbound, DIN 02557509 (tirzepatide; Schedule: Prescription) (read November 11, 2026)
  17. Health Canada Drug Product Database: Apo-Semaglutide Injection, DIN 02568012 (semaglutide; Schedule: Prescription) (read November 11, 2026)
  18. Sun Life: optional drug category, prior authorization from October 15, 2024 (August 13, 2024) (read October 2, 2026): Read via the Wayback snapshot of 2026-06-09.
  19. Canada Life: Wegovy prior authorization form M6453 ("not covered under all benefit plans") (read October 2, 2026)

Health Canada compliance: GLP1Prices.ca displays drug names, prices, and quantities only. We do not make therapeutic claims. This website does not provide medical advice. Consult your healthcare provider about medication options.

Related

Update log

  • New page: what the Saskatchewan Drug Plan pays for Ozempic, generic semaglutide, Mounjaro, Wegovy and Zepbound, from the Saskatchewan Formulary, its Appendix A and its bulletins, with cash prices and prescription options.
Check your insurance coverage